KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBT Margin (2016 - 2025)

Historic EBT Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 25.48%.

  • Bristol Myers Squibb's EBT Margin rose 113900.0% to 25.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.72%, marking a year-over-year increase of 312300.0%. This contributed to the annual value of 17.35% for FY2024, which is 361000.0% down from last year.
  • Bristol Myers Squibb's EBT Margin amounted to 25.48% in Q3 2025, which was up 113900.0% from 14.45% recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBT Margin peaked at 26.52% during Q1 2025, and registered a low of 97.06% during Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's EBT Margin had a median value of 16.3% in 2022 and averaged 10.93%.
  • As far as peak fluctuations go, Bristol Myers Squibb's EBT Margin tumbled by -1214900bps in 2024, and later soared by 1235800bps in 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBT Margin (Quarter) stood at 15.5% in 2021, then grew by 5bps to 16.3% in 2022, then dropped by -11bps to 14.59% in 2023, then crashed by -90bps to 1.42% in 2024, then soared by 1697bps to 25.48% in 2025.
  • Its EBT Margin was 25.48% in Q3 2025, compared to 14.45% in Q2 2025 and 26.52% in Q1 2025.